Cytokinetics Presents Additional Data From Assessment Comparing Aficamten To Placebo On Cardiac Endpoints In Adults With Non-Obstructive HCM At HFSA Annual Scientific Meeting 2026
Benzinga Newsdesk 2 weeks ago
News
Additional Analyses from ACACIA-HCM Further Characterize Exercise Performance, Treatment Effect, Dose Titration and Safety of Aficamten in Non-Obstructive HCMSOUTH SAN FRANCISCO, Calif., Oct. 12, 2026 (GLOBE NEWSWIRE)
Additional Analyses from ACACIA-HCM Further Characterize Exercise Performance, Treatment Effect, Dose Titration and Safety of Aficamten in Non-Obstructive HCM
SOUTH SAN FRANCISCO, Calif., Oct. 12, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that additional data from ACACIA-HCM (Assessment Comparing Aficamten to Placebo on Cardiac Endpoints In Adults with Non-Obstructive HCM) were presented at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2026 in Phoenix, AZ.